Sofosbuvir in crystalline form and process for its preparation

Abstract

Sofosbuvir in crystalline Form α, process for its production and use in pharmaceutical compositions.

1 . Sofosbuvir in crystalline Form α characterized by an XRPD comprising the following peaks: 7.96; 10.28; 12.32; 16.64; 18.56; 19.28; 19.88; 20.72; 21.88; 23.08; 24.24; 25.16; 27.00; 27.96±0.2° 2θ. 
     
     
         2 . A process for the preparation of Sofosbuvir according to  claim 1  wherein it comprises a step of dissolution of Sofosbuvir in ketones and a crystallization step of the solution obtained by said dissolution. 
     
     
         3 . The process according to  claim 2 , wherein said ketones are selected from the group consisting of acetone, methyl ethyl ketone, isobutyl methyl ketone and diethyl ketone. 
     
     
         4 . The process according to  claim 2 , wherein said ketones are selected from the group consisting of methyl ethyl ketone and isobutyl methyl ketone. 
     
     
         5 . The process according to  claim 2 , wherein said crystallization is obtained by cooling or by solvent evaporation. 
     
     
         6 . The process according to  claim 2  wherein it comprises:
 i. dissolution of Sofosbuvir in isobutyl methyl ketone at a temperature whithin the range of 50-60° C.; 
 ii. cooling the solution obtained from step i to a temperature of 20° C. till the precipitation of the product; 
 iii. filtration of the product obtained from step ii.; and 
 iv. under vacuum drying of the product obtained from step iii. 
 
     
     
         7 . A pharmaceutical composition comprising Sofosbuvir according to  claim 1 . 
     
     
         8 . The process according to  claim 2 , wherein said Sofosbuvir obtained with said process has a PSD wherein the size of the 90% of the particles is in the range of 10-50 μm. 
     
     
         9 . The process according to  claim 2 , wherein said Sofosbuvir obtained with said process has the following PSD: d(0.1): 1.831 μm; d(0.5): 5.263 μm; d(0.9): 20.369 μm.